



Supplemental Figure 1. *In vivo* cytokine responses of C57Bl/6 mice to GSL Ags. (A)

IFN- γ in the sera of mice injected with α GalCer or DB06-1 2 or 22 h earlier. Cytokine was measured by sandwich ELISA. 3 mice per group, error bars represent \pm SEM. (B) IL-4 in sera at 2 h post injection. Cytokine was measured by sandwich ELISA. 3 mice per group, error bars represent \pm SEM. (C) ICCS to measure IFN- γ production by splenic *i*NKT cells, gated as live cells, B220⁻, CD8 α ⁻, CD3 ϵ ⁺ and CD1d-tet⁺. (D) Summary graph of MFI IFN- γ of *i*NKT cells 2 h post injection. 3 mice per group. Error bars represent \pm SEM.


A.




B.




C.




D.




E.



F.



G.




Supplemental Figure 2. In vivo NK cell responses to glycolipid Ags. (A)

Representative flow cytometry plots for intracellular IFN- γ showing splenic NK cells, gated as live cells that are B220⁻, CD3 ϵ ⁻, and NK1.1⁺. Data were obtained from mice injected with no GSL (mock), α GalCer or DB06-1 and analyzed at 24 h post injection.

(B) Representative data of one of three experiments showing % IFN- γ ⁺ NK cells at 24 h post injection with 3 mice per group. (C) Staining of splenic NK cells in control mice and mice treated with anti-Asialo-GM1 antibody showing the effectiveness of NK cell depletion. NK cells were gated as live cells that were B220⁻, CD3 ϵ ⁻ and NK1.1⁺. Un-injected mice (mock) were compared to anti-asialo-GM1 treated mice. (D)

Representative data from one of two experiments depicting the percent NK cell depletion with anti-asialo-GM1 treatment. (E) Percent *i*NKT cells after anti-asialo-GM1 Ab treatment, showing that *i*NKT cells were not affected. (F) IFN- γ in sera comparing WT and IL-12^{-/-} mice 24 h post injection. Combined data from 2 different experiments, 5 mice per group. (G) ICCS IFN- γ from splenic NK cells 24 h post injection comparing WT and IL-12^{-/-} mice. Representative data from one of two experiments.



Supplemental Figure 3. DC responses in GSL injected mice. (A) IL-4 in sera at 2 h after injection of DB06-1 measured by sandwich ELISA comparing *Cd11c-Cre* mice (Cre^+) to *Cd11c-Cre* controls lacking the Cre transgene (Cre^-). (B,C) Splenic $CD8\alpha^+$ DCs ($CD11c^+ CD8\alpha^+$) were analyzed by flow cytometry for the indicated cell surface molecules at 2 and 24 h following i.v. injection of 1 μ g of either DB06-1 or α GalCer (gray, α GalCer; black, DB06-1). Changes in cell surface expression molecules are shown as the fold increase compared to uninjected control mice. CD1d and activation markers CD80 and CD86 are shown in (B) and GSL-CD1d complex formation as measured by L363 is shown in (C). Data shown are representative of one of two experiments showing means \pm SD for triplicate mice in each group.

Supplemental Table I. Data collection and refinement statistics from CD1d-DB06-1-TCR mouse ternary crystal structure (PDB ID 4ZAK).

Data collection statistics	CD1d-DB06-1-TCR
Space group	C222 ₁
Cell dimension	
<i>a, b, c</i> , (Å)	78.9, 190.5, 150.8
<i>α, β, γ</i> , (°)	90.0, 90.0, 90.0
Resolution range (Å) [outer shell]	50-2.83 (2.93-2.83)
No. reflections	27210 (2706)
R _{merge} (%)	12.2 (57.3)
R _{pim} (%)	6.1 (28.2)
Multiplicity	3.9 (3.8)
Average I/σI	10.4 (1.9)
Completeness (%)	98.1 (98.6)
Refinement statistics	
No. atoms	6,341
Protein	6,225
Ligand	60
Carbohydrate	56
R/R _{free} (%)	21.6/25.6
Ramachandran plot (%)	
Favored	97.7
Allowed	100
R.m.s. deviations	
Bonds (Å)	0.006
Angles (°)	0.915
B-factors (Å ²)	
Protein	50.2
Ligand	40.4
Carbohydrate	58.9